ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
A phase 3 trial of Dacomitinib and Erlotinib in Non-small-cell lung cancer, run by Pfizer, completed.
Overview
ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT01360554 by Pfizer, with 878 participants recorded, started 2011-06-16 and reaching its primary completion in 2013-09-30. Interventions recorded: Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804. Conditions recorded: Non-Small Cell Lung Cancer.
Linked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC
Shares Dacomitinib, Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TrialEGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
Shares Dacomitinib, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TreatmentPF-07248144
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TreatmentPF-08046054
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialEfficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.